The new oral therapy Divarasib has shown to reduce the risk of death by 44% and the risk of disease progression by 42% in patients with non-small cell lung cancer with the Kras G12C mutation, according to an international phase 3 study. #TumorePolmonare #TerapiaOrale #Divarasib (translated)
www.ilmessaggero.it
Tumore al polmone, la nuova terapia orale Divarasib riduce del 44% il rischio di morte: cos'è, effetti collaterali, come funziona
